Shams Najafabadi Hoda, Daftarian Narsis, Ahmadieh Hamid, Soheili Zahra-Soheila
National institute Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2017 Aug;20(8):525-537.
Age-related macular degeneration as the major cause of blindness in the elderly population has remained at the epicenter of clinical research in ophthalmology. This retinal disorder is characterized by the photoreceptor and retinal pigment epithelial cells loss, occurring within the macula. The disease represents a spectrum of clinical manifestations. It is a multifactorial disease resulting from a combination of genetic predispositions and environmental risk factors. AMD is classified into two different types, dry and wet. Wet AMD is in close relation with angiogenesis and inflammatory processes.A variety of anti-angiogenesis and anti-inflammatory drugs have been proposed for the treatment of the disease. The purpose of this paper is to briefly review the pharmacological therapies of the wet form of AMD and focus on new drugs that are currently in different stages of research and development.
年龄相关性黄斑变性作为老年人群失明的主要原因,一直是眼科临床研究的核心。这种视网膜疾病的特征是黄斑区内光感受器和视网膜色素上皮细胞的丧失。该疾病表现出一系列临床表现。它是一种由遗传易感性和环境危险因素共同作用导致的多因素疾病。年龄相关性黄斑变性分为干性和湿性两种不同类型。湿性年龄相关性黄斑变性与血管生成和炎症过程密切相关。已经提出了多种抗血管生成和抗炎药物用于治疗该疾病。本文的目的是简要回顾湿性年龄相关性黄斑变性的药物治疗方法,并重点关注目前处于不同研发阶段的新药。